Literature DB >> 15768329

Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification.

Claudio Viscoli1, Oliviero Varnier, Marco Machetti.   

Abstract

Determinations of the type and setting of empirical therapy for immunocompromised patients with fever are complicated by the characteristics of the underlying illness and the effects of treatments already received, as well as by changing microbiological patterns and trends in drug resistance at national and institutional levels. Several systems have been proposed to distinguish patients who could benefit from outpatient antibiotic therapy from patients who require hospitalization. Practical considerations may decide whether the necessary monitoring during the period of neutropenia can be achieved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15768329     DOI: 10.1086/427329

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  52 in total

1.  Neutropenia enhances lung dendritic cell recruitment in response to Aspergillus via a cytokine-to-chemokine amplification loop.

Authors:  Stacy J Park; Marie D Burdick; William K Brix; Mark H Stoler; David S Askew; Robert M Strieter; Borna Mehrad
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Attitudes of physicians toward assessing risk and using granulocyte colony-stimulating factor as primary prophylaxis in patients receiving chemotherapy associated with an intermediate risk of febrile neutropenia.

Authors:  Gilles Freyer; Ewa Kalinka-Warzocha; Konstantinos Syrigos; Mihai Marinca; Giuseppe Tonini; Say Liang Ng; Zee Wan Wong; Antonio Salar; Guenther Steger; Mahmoud Abdelsalam; Lucy DeCosta; Zsolt Szabo
Journal:  Med Oncol       Date:  2015-08-28       Impact factor: 3.064

3.  Carbapenem versus Cefepime or Piperacillin-Tazobactam for Empiric Treatment of Bacteremia Due to Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Patients with Hematologic Malignancy.

Authors:  Grace E Benanti; Anne Rain T Brown; Terri Lynn Shigle; Jeffrey J Tarrand; Micah M Bhatti; Patrick M McDaneld; Samuel A Shelburne; Samuel L Aitken
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

4.  Tigecycline resistance among Klebsiella pneumoniae isolated from febrile neutropenic patients.

Authors:  Sherein G Elgendy; Muhammad R Abdel Hameed; Mohamed A El-Mokhtar
Journal:  J Med Microbiol       Date:  2018-05-25       Impact factor: 2.472

5.  Novel antifungal drugs against fungal pathogens: do they provide promising results for treatment?

Authors:  Habip Gedik; Funda Şimşek; Taner Yıldırmak; Arzu Kantürk; Deniz Arıca; Demet Aydın; Naciye Demirel; Osman Yokuş
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

6.  Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

Authors:  Rémi Goupil; Soumeya Brachemi; Annie-Claire Nadeau-Fredette; Clément Déziel; Yves Troyanov; Valery Lavergne; Stéphan Troyanov
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

Review 7.  The rise and rise of Staphylococcus aureus: laughing in the face of granulocytes.

Authors:  S Anwar; L R Prince; S J Foster; M K B Whyte; I Sabroe
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia.

Authors:  Yitang Li; Yonghui Jia; Muriel Pichavant; Fabien Loison; Bara Sarraj; Anongnard Kasorn; Jian You; Bryanne E Robson; Dale T Umetsu; Joseph P Mizgerd; Keqiang Ye; Hongbo R Luo
Journal:  Blood       Date:  2009-03-13       Impact factor: 22.113

9.  Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa.

Authors:  C Gudiol; A Albasanz-Puig; J Laporte-Amargós; N Pallarès; A Mussetti; I Ruiz-Camps; P Puerta-Alcalde; E Abdala; C Oltolini; M Akova; M Montejo; M Mikulska; P Martín-Dávila; F Herrera; O Gasch; L Drgona; H Paz Morales; A-S Brunel; E García; B Isler; W V Kern; I Morales; G Maestro-de la Calle; M Montero; S S Kanj; O R Sipahi; S Calik; I Márquez-Gómez; J I Marin; M Z R Gomes; P Hemmatti; R Araos; M Peghin; J L Del Pozo; L Yáñez; R Tilley; A Manzur; A Novo; J Carratalà
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

10.  Managing infection in cancer patients and other immunocompromised children.

Authors:  Russell W Steele
Journal:  Ochsner J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.